Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.
作者信息
Kudo Masatoshi
机构信息
Editor-in-Chief, Liver Cancer, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2022 Feb 18;11(2):87-93. doi: 10.1159/000523702. eCollection 2022 Apr.
Abstract
摘要
相似文献
1
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.度伐利尤单抗联合曲美木单抗：用于不可切除肝细胞癌的新型联合免疫疗法。
Liver Cancer. 2022 Feb 18;11(2):87-93. doi: 10.1159/000523702. eCollection 2022 Apr.
2
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.度伐鲁单抗单药治疗及联合替西木单抗与化疗用于未经治疗的不可切除局部晚期或转移性尿路上皮癌患者（DANUBE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21.
3
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma.300毫克单剂量曲美木单抗联合度伐利尤单抗1500毫克每4周一次（STRIDE方案）用于不可切除肝细胞癌患者的群体药代动力学和暴露-反应分析
J Clin Pharmacol. 2023 Nov;63(11):1221-1231. doi: 10.1002/jcph.2288. Epub 2023 Jun 22.
4
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.度伐利尤单抗联合或不联合替西木单抗治疗复发性或转移性头颈部鳞状细胞癌患者：EAGLE，一项随机、开放标签的 III 期研究。
Ann Oncol. 2020 Jul;31(7):942-950. doi: 10.1016/j.annonc.2020.04.001. Epub 2020 Apr 12.
5
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.度伐利尤单抗联合曲美木单抗治疗非小细胞肺癌的安全性和抗肿瘤活性：一项多中心1b期研究
Lancet Oncol. 2016 Mar;17(3):299-308. doi: 10.1016/S1470-2045(15)00544-6. Epub 2016 Feb 6.
6
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合或不联合 Tremelimumab 与单用依托泊苷联合顺铂一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、3 期临床试验的更新结果。
Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
7
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.度伐利尤单抗联合或不联合替西木单抗与标准化疗用于转移性非小细胞肺癌一线治疗的 MYSTIC 期 3 随机临床试验。
JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237.
8
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.加拿大癌症试验组BR34：度伐利尤单抗和曲美木单抗联合或不联合铂类化疗用于转移性非小细胞肺癌患者的随机2期试验。
J Thorac Oncol. 2022 Mar;17(3):434-445. doi: 10.1016/j.jtho.2021.10.023. Epub 2021 Nov 17.
9
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.度伐利尤单抗联合或不联合 Tremelimumab 加铂类依托泊苷一线治疗广泛期小细胞肺癌：CASPIAN 的 3 年总生存更新。
ESMO Open. 2022 Apr;7(2):100408. doi: 10.1016/j.esmoop.2022.100408. Epub 2022 Mar 10.
10
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.度伐利尤单抗联合曲美木单抗治疗不可切除肝细胞癌
Hepatobiliary Surg Nutr. 2022 Aug;11(4):592-596. doi: 10.21037/hbsn-22-143.
引用本文的文献
1
Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.经动脉化疗栓塞联合乐伐替尼和PD-1抑制剂治疗的晚期不可切除肝癌的长期生存情况
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf058.
2
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families.揭示不同蛋白质家族中免疫检查点蛋白的作用机制和治疗潜力。
Front Immunol. 2025 Apr 28;16:1499663. doi: 10.3389/fimmu.2025.1499663. eCollection 2025.
3
Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.STE20型激酶STK25抑制在预防和治疗代谢性诱导肝细胞癌中的治疗潜力
Cell Mol Gastroenterol Hepatol. 2025 Feb 28;19(7):101485. doi: 10.1016/j.jcmgh.2025.101485.
4
Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8CD69 T cells.个性化新抗原水凝胶疫苗联合PD-1和CTLA-4双重阻断通过激活肿瘤内CD8CD69 T细胞引发肝转移瘤的抗肿瘤反应。
J Immunother Cancer. 2024 Dec 18;12(12):e009543. doi: 10.1136/jitc-2024-009543.
5
Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.抗程序性死亡蛋白1自身抗体可预测接受阿替唑单抗/贝伐单抗治疗的肝细胞癌患者的生存期。
Gastro Hep Adv. 2024 Aug 2;3(8):1138-1147. doi: 10.1016/j.gastha.2024.07.018. eCollection 2024.
6
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.在不可切除的肝细胞癌中，阿替利珠单抗联合贝伐珠单抗二线治疗后，度伐利尤单抗联合替西木单抗的真实世界疗效和安全性。
Medicine (Baltimore). 2024 Aug 23;103(34):e39289. doi: 10.1097/MD.0000000000039289.
7
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.肺癌中 PD-1/PD-L1 和 CTLA-4 的双重阻断免疫疗法。
J Hematol Oncol. 2024 Jul 27;17(1):54. doi: 10.1186/s13045-024-01581-2.
8
Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma.探讨局部区域联合治疗与免疫治疗在肝细胞癌治疗中的疗效与安全性。
Biomedicines. 2024 Jun 27;12(7):1432. doi: 10.3390/biomedicines12071432.
9
Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.沙特阿拉伯肝细胞癌治疗模式及改善管理的建议
J Hepatocell Carcinoma. 2024 Feb 16;11:349-362. doi: 10.2147/JHC.S442842. eCollection 2024.
10
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.日本肝细胞癌的当前治疗策略
Liver Cancer. 2023 Oct 3;12(6):497-509. doi: 10.1159/000534304. eCollection 2023 Dec.
本文引用的文献
1
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
2
Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?非酒精性脂肪性肝炎相关肝细胞癌对免疫疗法的反应受损？
Liver Cancer. 2021 Jul;10(4):289-295. doi: 10.1159/000517841. Epub 2021 Jul 2.
3
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.替西木单抗联合度伐利尤单抗治疗不可切除肝细胞癌患者的安全性、疗效和药效学：一项 I/II 期研究的随机扩展。
J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22.
4
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.抗PD-1/PD-L1单药疗法对肝细胞癌的疗效有限。
Liver Cancer. 2020 Dec;9(6):629-639. doi: 10.1159/000512170. Epub 2020 Oct 26.
5
Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.钆塞酸二钠增强磁共振成像可预测肝细胞癌中WNT/β-连环蛋白突变及对免疫检查点抑制剂治疗的耐药性。
Liver Cancer. 2020 Sep;9(5):479-490. doi: 10.1159/000509554. Epub 2020 Aug 20.
6
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.纳武利尤单抗联合伊匹木单抗治疗索拉非尼治疗后晚期肝细胞癌患者的疗效和安全性：CheckMate 040 随机临床试验。
JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12.
7
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
8
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
9
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.肝细胞癌全身治疗的新时代：阿替利珠单抗联合贝伐珠单抗联合疗法。
Liver Cancer. 2020 Apr;9(2):119-137. doi: 10.1159/000505189. Epub 2020 Mar 5.
10
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.通过 Fc 工程化抗 CTLA-4 抗体对肿瘤免疫中的人 Treg 和效应 T 细胞进行差异化控制。
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):609-618. doi: 10.1073/pnas.1812186116. Epub 2018 Dec 26.
Zotero 插件